HF Science News from AHA Scientific Sessions 2020 Dr Han Naung Tun (Henry Han) MBBS, MD, FACTM

1. HF Science News from AHA
Scientific Sessions 2020
Dr Han Naung Tun (Henry Han)
MBBS, MD, FACTM
Heart and Vascular Centre, Rangoon
National Representative Heart Failure Specialist of Tomorrow for Myanmar in HFA and Ambassador of
Echocardiography in EACVI, ESC
Ambassador of Tele-Cardiology Working Group for Asia in ISFTeH
@HanCardiomd

2. Declaration of interest
None to disclose

3. Global Approach to Lowering Adverse Cardiac Outcomes Through Improving
Contractility in Heart Failure - GALACTIC-HF
Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalizations and
Mortality in Iron Deficient Subjects Admitted for Acute Heart Failure - AFFIRM-AHF
Empaglifozin on LV Volume SUGAR-DM-HF and EMPA-TROPISM (ATRU-4)
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post
Worsening Heart Failure SOLOIST-WHF Trial

6. John R. Teerlink, M.D. the GALACTIC-HF Investigators* ,
NEJM, 2020
In patient with HF , omecamtive mecarbil statically
significant reduce the risk of primary composite outcome
(first HF event or CV event)

7. Conclusion
Selectively tagging the cardiac sarcomere with omencative mecarbil, the first in
class myotrope is novel approach to improving cardiac function and
cardiovascular outcomes
In patient with HF , omecamtive mecarbil statically significant reduce the risk of
primary composite outcome (first HF event or CV event)
The pattern of AEs, including MI, VAs , were similar in the omecamtive mecarbil
and placebo group
Further analyses of GALATIC HF will provide grater insight into subgroups who
may demonstrate grater benefit, such as patients with lower EF in whom
improving cardiac function may have a greater role

8. AFFIRM-AHF
The Lancet DOI: (10.1016/S0140-6736(20)32339-4

9. AFFIRM-AHF Trial , The Lancet DOI: (10.1016/S0140-6736(20)32339-4

10. AFFIRM-AHF Trial , The Lancet DOI: (10.1016/S0140-6736(20)32339-4

11. Effect of Empagliflozin on Left Ventricular Volumes in
Patients with Type 2 Diabetes, or Prediabetes, and
Heart Failure with Reduced Ejection Fraction
(SUGAR-DM-HF)
Randomized Trial of Empagliflozin in Non-Diabetic Patients
with Heart Failure and Reduced Ejection Fraction
EMPA-TROPISM (ATRU-4)
Matthew M. Y. Lee et al, Cir 2020
Carlos G. Santos-Gallego et al, JACC ,2020
 Total number of
pts: 84
 Duration of
follow-up: 6
months
 Mean patient
age: 61.9 years
 Percentage
female: 36%
 N- 105
patients
 Mean age
68.7 [SD
11.1] years

12. Sotagliflozin in Patients with
Diabetes and Recent
Worsening Heart Failure
(SOLOIST-WHF Trial)
Deepak L. Bhatt et al
In patients with diabetes
and recent worsening heart
failure, sotagliflozin
therapy, initiated before or
shortly after discharge,
resulted in a significantly
lower total number of
deaths from cardiovascular
causes and hospitalizations
and urgent visits for heart
failure than placebo.
DL Bhatt et al. SOLOIST-WHF Trial N Engl J Med 2020

13. Thank You
@HanCardiomd